金宗浩, 党云文. 球菌类毒素联合内分泌药物治疗晚期复发性乳腺癌临床研究[J]. 中国肿瘤临床, 2005, 32(1): 34-36.
引用本文: 金宗浩, 党云文. 球菌类毒素联合内分泌药物治疗晚期复发性乳腺癌临床研究[J]. 中国肿瘤临床, 2005, 32(1): 34-36.
shu
Jin Zonghao, Dang Yunwen. Clinical Study on Recurrence of Advanced Breast Cancer Treated by LIFEIN in Combination with Incretion Drug[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2005, 32(1): 34-36.
Citation: Jin Zonghao, Dang Yunwen. Clinical Study on Recurrence of Advanced Breast Cancer Treated by LIFEIN in Combination with Incretion Drug[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2005, 32(1): 34-36.
shu

球菌类毒素联合内分泌药物治疗晚期复发性乳腺癌临床研究

Clinical Study on Recurrence of Advanced Breast Cancer Treated by LIFEIN in Combination with Incretion Drug

    摘要
  • 摘要: 目的:研究球菌类毒素制剂在提高晚期复发性乳腺癌治疗效果方面的作用。方法:78例有局部复发或远处转移的晚期乳腺癌患者,随机分为治疗组(35例)和对照组(43例)。治疗组应用球菌类毒素甘露聚糖肽(制剂名“力尔凡”由长春力尔凡药业有限公司提供),联合法乐通治疗;对照组单用法乐通治疗。力尔凡应用方法:第1～7d皮下注射力尔凡10mg/d,第8～14d静脉滴注20mg/d,15～21d静脉滴注30mg/d,22～28d静脉滴注30mg/d,29～64d静脉滴注40mg/d。法乐通60mg/d,口服共64d。全部病例的疗效用显效(CR)、有效(PR)、无效(NC)、进展(PD)、有效率(CR+PR)等进行临床评估,用癌胚抗原(Carcino-embryonicantigen,CEA)、糖类抗原CA-153检测进行实验室评估。结果:全部病例均按要求完成治疗。治疗组总缓解率为94.29%,对照组为76.74%(P<0.01)。结论:力尔凡与内分泌治疗药物联合应用,能提高晚期复发性乳腺癌患者的生存质量和生存率。

     

    Abstract: Objective:To study the improved therapeutic effect of LIFEIN for the patients with recurrence of advanced breast cancer. Methods: Seventy-eight cases of advanced breast cancers with local recurrent metastases were divided into two groups: the treatment group (35 cases) and the controls(43 cases). The treatment group was treated by LIFEIN combining with Fareston incretion medical, and the control group treated with Fareston alone. The treatment method of LIFEIN: 10mg/d x7 subcuta-neously; then 20mg/dx7, 30mg/dx7 and 40m/dx36, intravenously and successively. Endocrine therapy with Fareston: 60mg/d orally for 64 days. All the cases were evaluated with CR,PR,NC,PD and effective rate. With Carcin(卜embryonic antigen (CEA) and CA一153. Results: The treatemnts were completed in all the patients. The efficacy was 85.71% in the treatment group and 76.74% in the controls (P>0.01). Conclusion: LIFEIN can improve the survival rate and life quality of the patients with metastries of breast cancer.

     

    • HTML全文
    • 参考文献(14)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回